Dexcom (0A4M) Share Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0A4M Analyst Ratings

Strong Buy

17 Buy

4 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Dexcom

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0A4M Stock 12 Month Forecast

Average Price Target

$88.05

▲(57.23% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is $88.05 with a high forecast of $112.00 and a low forecast of $75.00. The average price target represents a 57.23% change from the last price of $56.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"55":"$55","84":"$84","113":"$113","69.5":"$69.5","98.5":"$98.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$112.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[55,69.5,84,98.5,113],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.6,60.861538461538466,65.12307692307692,69.38461538461539,73.64615384615385,77.90769230769232,82.16923076923078,86.43076923076923,90.6923076923077,94.95384615384616,99.21538461538461,103.47692307692307,107.73846153846154,{"y":112,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.6,59.019230769230774,61.43846153846154,63.85769230769231,66.27692307692308,68.69615384615385,71.11538461538461,73.53461538461539,75.95384615384616,78.37307692307692,80.79230769230769,83.21153846153845,85.63076923076923,{"y":88.05,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.6,58.01538461538462,59.43076923076923,60.84615384615385,62.261538461538464,63.676923076923075,65.09230769230768,66.50769230769231,67.92307692307692,69.33846153846154,70.75384615384615,72.16923076923077,73.58461538461538,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":70.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.396,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.77,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$112.00

Average Price Target$88.05

Lowest Price Target$75.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Steven Silver

Argus Research

$100→$90

Buy

60.71%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM) and DENTSPLY SIRONA (NASDAQ: XRAY)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

11/07/25

Dexcom: A Compelling Buy Amid Operational Improvements and Market Opportunities

Richard Newitter

Truist Financial

$94→$82

Buy

46.43%

Upside

Reiterated

11/03/25

DexCom price target lowered to $82 from $94 at TruistDexCom price target lowered to $82 from $94 at Truist

Matt Miksic

Barclays

$98→$80

Hold

42.86%

Upside

Reiterated

11/03/25

DexCom price target lowered to $80 from $98 at BarclaysDexCom price target lowered to $80 from $98 at Barclays

Travis Steed

Bank of America Securities

$105→$100

Buy

78.57%

Upside

Reiterated

11/03/25

Bank of America Securities Remains a Buy on Dexcom (DXCM)

Danielle Antalffy

UBS

$106→$95

Buy

69.64%

Upside

Reiterated

11/03/25

DexCom price target lowered to $95 from $106 at UBSDexCom price target lowered to $95 from $106 at UBS

Lila Implantra

TR | OpenAI - 4o

$75→$64

Hold

14.29%

Upside

Reiterated

11/01/25

AI Generated ArticleAI Generated Article

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

10/31/25

Oppenheimer Remains a Hold on Dexcom (DXCM)

Jeff Johnson

Robert W. Baird

$90→$82

Buy

46.43%

Upside

Reiterated

10/31/25

DexCom price target lowered to $82 from $90 at BairdDexCom price target lowered to $82 from $90 at Baird

Matthew Taylor

Jefferies

$112

Buy

100.00%

Upside

Reiterated

10/31/25

Dexcom (DXCM) Gets a Buy from Jefferies

Joanne Wuensch

Citi

$85→$75

Buy

33.93%

Upside

Reiterated

10/31/25

DexCom price target lowered to $75 from $85 at CitiDexCom price target lowered to $75 from $85 at Citi

Robbie Marcus

J.P. Morgan

$90→$75

Hold

33.93%

Upside

Reiterated

10/31/25

DexCom price target lowered to $75 from $90 at JPMorganDexCom price target lowered to $75 from $90 at JPMorgan

Jonathan Block

Stifel Nicolaus

$85

Buy

51.79%

Upside

Reiterated

10/31/25

Stifel Nicolaus Keeps Their Buy Rating on Dexcom (DXCM)

Larry Biegelsen

Wells Fargo

$98→$93

Buy

66.07%

Upside

Reiterated

10/31/25

DexCom price target lowered to $93 from $98 at Wells FargoDexCom price target lowered to $93 from $98 at Wells Fargo

William Plovanic

Canaccord Genuity

$106→$99

Buy

76.79%

Upside

Reiterated

10/31/25

DexCom price target lowered to $99 from $106 at CanaccordDexCom price target lowered to $99 from $106 at Canaccord

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Steven Silver

Argus Research

$100→$90

Buy

60.71%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM) and DENTSPLY SIRONA (NASDAQ: XRAY)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

11/07/25

Dexcom: A Compelling Buy Amid Operational Improvements and Market Opportunities

Richard Newitter

Truist Financial

$94→$82

Buy

46.43%

Upside

Reiterated

11/03/25

DexCom price target lowered to $82 from $94 at TruistDexCom price target lowered to $82 from $94 at Truist

Matt Miksic

Barclays

$98→$80

Hold

42.86%

Upside

Reiterated

11/03/25

DexCom price target lowered to $80 from $98 at BarclaysDexCom price target lowered to $80 from $98 at Barclays

Travis Steed

Bank of America Securities

$105→$100

Buy

78.57%

Upside

Reiterated

11/03/25

Bank of America Securities Remains a Buy on Dexcom (DXCM)

Danielle Antalffy

UBS

$106→$95

Buy

69.64%

Upside

Reiterated

11/03/25

DexCom price target lowered to $95 from $106 at UBSDexCom price target lowered to $95 from $106 at UBS

Lila Implantra

TR | OpenAI - 4o

$75→$64

Hold

14.29%

Upside

Reiterated

11/01/25

AI Generated ArticleAI Generated Article

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

10/31/25

Oppenheimer Remains a Hold on Dexcom (DXCM)

Jeff Johnson

Robert W. Baird

$90→$82

Buy

46.43%

Upside

Reiterated

10/31/25

DexCom price target lowered to $82 from $90 at BairdDexCom price target lowered to $82 from $90 at Baird

Matthew Taylor

Jefferies

$112

Buy

100.00%

Upside

Reiterated

10/31/25

Dexcom (DXCM) Gets a Buy from Jefferies

Joanne Wuensch

Citi

$85→$75

Buy

33.93%

Upside

Reiterated

10/31/25

DexCom price target lowered to $75 from $85 at CitiDexCom price target lowered to $75 from $85 at Citi

Robbie Marcus

J.P. Morgan

$90→$75

Hold

33.93%

Upside

Reiterated

10/31/25

DexCom price target lowered to $75 from $90 at JPMorganDexCom price target lowered to $75 from $90 at JPMorgan

Jonathan Block

Stifel Nicolaus

$85

Buy

51.79%

Upside

Reiterated

10/31/25

Stifel Nicolaus Keeps Their Buy Rating on Dexcom (DXCM)

Larry Biegelsen

Wells Fargo

$98→$93

Buy

66.07%

Upside

Reiterated

10/31/25

DexCom price target lowered to $93 from $98 at Wells FargoDexCom price target lowered to $93 from $98 at Wells Fargo

William Plovanic

Canaccord Genuity

$106→$99

Buy

76.79%

Upside

Reiterated

10/31/25

DexCom price target lowered to $99 from $106 at CanaccordDexCom price target lowered to $99 from $106 at Canaccord

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dexcom

1 Month

xxx

Success Rate

15/26 ratings generated profit

Average Return

+2.80%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.69% of your transactions generating a profit, with an average return of +2.80% per trade.

3 Months

xxx

Success Rate

25/38 ratings generated profit

Average Return

+10.45%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.79% of your transactions generating a profit, with an average return of +10.45% per trade.

1 Year

Joanne WuenschCiti

Success Rate

22/37 ratings generated profit

Average Return

+14.17%

reiterated a buy rating 10 days ago

Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 59.46% of your transactions generating a profit, with an average return of +14.17% per trade.

2 Years

xxx

Success Rate

18/32 ratings generated profit

Average Return

+27.04%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 56.25% of your transactions generating a profit, with an average return of +27.04% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A4M Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0A4M has received 40 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 0A4M average Analyst price target in the past 3 months is 88.05.

Each month's total comprises the sum of three months' worth of ratings.

0A4M Financial Forecast

0A4M Earnings Forecast

Next quarter’s earnings estimate for 0A4M is $0.65 with a range of $0.59 to $0.69. The previous quarter’s EPS was $0.61. 0A4M beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0A4M has Preformed in-line its overall industry.

0A4M Sales Forecast

Next quarter’s sales forecast for 0A4M is $1.24B with a range of $1.23B to $1.25B. The previous quarter’s sales results were $1.21B. 0A4M beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0A4M has Preformed in-line its overall industry.

0A4M Stock Forecast FAQ

What is GB:0A4M’s average 12-month price target, according to analysts?

Based on analyst ratings, Dexcom’s 12-month average price target is 88.05.

What is GB:0A4M’s upside potential, based on the analysts’ average price target?

Dexcom has 57.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Dexcom a Buy, Sell or Hold?

Dexcom has a consensus rating of Strong Buy, which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.

What is Dexcom’s share price target?

The average share price target for Dexcom is 88.05. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $112.00 ,and the lowest forecast is $75.00. The average share price target represents 57.23% Increase from the current price of $56.

What do analysts say about Dexcom?

Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Dexcom?

To buy shares of GB:0A4M, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Dexcom (0A4M) Share Forecast & Price Target

0A4M Analyst Ratings

0A4M Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dexcom

0A4M Analyst Recommendation Trends

0A4M Financial Forecast

0A4M Earnings Forecast

0A4M Sales Forecast

0A4M Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts